What is it about?
To test the hypothesis that polymorphism within the gene-linked polymorphic region (5-HTTLPR) and second intron of SLC6A4 gene (STin2) is associated with selective serotonin-reuptake inhibitors (SSRIs) response in subjects with premature ejaculation (PE).
Photo by David Clode on Unsplash
Why is it important?
Premature ejaculation (PE) is the most prevalent male sexual dysfunction. The prevalence of PE varies widely among societies. From primary-care settings the reported prevalence of PE is 31% in the USA and 66% in Germany. The current most popular pharmacotherapeutic approach to treat PE is ‘off-label’ administration of selective serotonin (5-hydroxytryptamine, 5-HT)-reuptake inhibitors (SSRIs, e.g. paroxetine, fluoxetine, sertraline, citalopram, and escitalopram), which are reported to be effective for treating PE.
Read the Original
This page is a summary of: Analysis of association between the 5-HTTLPR and STin2 polymorphisms in the serotonin-transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation, BJU International, January 2010, Wiley, DOI: 10.1111/j.1464-410x.2009.08714.x.
You can read the full text:
The following have contributed to this page